Drug Topics
OCTOBER 1, 2024
Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.
Pharmacy Times
OCTOBER 1, 2024
The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 1, 2024
Often, women with sickle cell disease are told not to have kids. They might come to an appointment, happily pregnant, only for the doctor to tell them they shouldn’t be. They might be preparing for a scheduled C-section when their OB-GYN says that this pregnancy has gone smoothly but the next one could kill them. The illness is associated with an increased risk of serious pregnancy complications, which warrants a discussion — but sometimes that discussion can blur the line between
Fierce Pharma
OCTOBER 1, 2024
Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 1, 2024
A year ago last week, Jeanne Marrazzo stepped into a very big pair of shoes. Marrazzo became the first new director of the National Institute of Allergy and Infectious Diseases in decades, taking over a job held for 38 years by Anthony Fauci, whose long-term status as a science god in Washington gave way to Covid-19 fall guy in some quarters during and after the pandemic.
Drug Topics
OCTOBER 1, 2024
Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
OCTOBER 1, 2024
Two key senators are urging the Federal Trade Commission to investigate "co-manufacturing" arrangements that they fear pharmacy benefit managers may be using to stymie competition. | Two key senators are urging the Federal Trade Commission to investigate "co-manufacturing" arrangements that they fear pharmacy benefit managers may be using to stymie competition.
STAT
OCTOBER 1, 2024
Across all kinds of cancer, Black Americans have higher rates of mortality and, often, more aggressive forms of the disease. A growing body of research suggests the reasons may not have to do with African ancestry as much as social and environmental factors like racism, housing discrimination , and — according to a new study — exposure to pollution.
Pharmacy Times
OCTOBER 1, 2024
A recent study found that indoor allergen exposure, including mouse and cockroach allergens, led to an increased risk of respiratory viral infections in children with asthma.
Drug Topics
OCTOBER 1, 2024
Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 1, 2024
Ustekinumab is a human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, which play a rule in the inflammatory and immune responses.
Fierce Healthcare
OCTOBER 1, 2024
Rippl, a virtual dementia care company, secured $23 million in series A funding to expand its services to patients in more states. | Rippl, a virtual dementia care startup, plans to use its series A funding to expand into new states, build out its value-based contracts and participate in CMS' GUIDE program.
Pharmacy Times
OCTOBER 1, 2024
Treatment for primary coenzyme Q10 (CoQ10) deficiency can include high-dose oral CoQ10 supplementation, but not all patients respond to this treatment.
Fierce Healthcare
OCTOBER 1, 2024
A new analysis points to troubling trends in the U.S. healthcare market as costs continue to rise but health outcomes are declining. | "The inputs of the U.S. healthcare system, as measured by cost, exceed the outputs, as measured by the actual value or benefits received by Americans," Sanjula Jain, Ph.D., Trilliant Health's chief research officer, said.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
OCTOBER 1, 2024
Navenibart was developed to aid treatment of hereditary angioedema (HAE) to provide swift and sustained HAE attack prevention through administration every 3 to 6 months.
Fierce Healthcare
OCTOBER 1, 2024
Hospital programs providing at-home acute care are widely appreciated by patients and clinicians but still don’t have a bulletproof argument in respect to quality and costs as compared to a brick-a | A new 79-page government report on the soon-to-expire Acute Hospital Care at Home initiative outlines both clear-cut and muted wins for advocates.
Pharmacy Times
OCTOBER 1, 2024
The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.
STAT
OCTOBER 1, 2024
Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup led by a chief executive hot off of his third acquisition deal. Atlas, Bain, and RTW Investments announced Tuesday that they have co-led a $400 million Series A financing for a new Boston-area startup company called Kailera Therapeutics.
Fierce Healthcare
OCTOBER 1, 2024
Bessemer Venture Partners released a new report that identifie | Bessemer Venture Partners has released a new road map outlining opportunities for artificial intelligence in healthcare. The VC firm also lists its six investing criteria for AI.
Pharmacy Times
OCTOBER 1, 2024
Karen Merrill discusses her experiences in pharmacy with plans to celebrate her niece, a first-year pharmacist.
Fierce Healthcare
OCTOBER 1, 2024
Orlando Health has wrapped up its purchase of five Birmingham, Alabama-area hospitals’ majority ownership stakes from Tenet Healthcare, the systems announced Tuesday morning. | Brookwood Baptist Health is a Birmingham, Alabama-area joint venture with Baptist Health System, which remains a partner after Orlando Health's majority share purchase.
pharmaphorum
OCTOBER 1, 2024
Learn how Advanced Clinical ensures compliance through the Functional Point of Contact (FPOC) story. Explore their innovative approach to maintaining regulatory standards.
STAT
OCTOBER 1, 2024
A U.S. lawmaker is pushing the Food and Drug Administration to provide more guidance on listing patents for drug-and-device combination products, such as asthma inhalers and auto-injectors for diabetes treatments, in a highly important agency registry known as the Orange Book. In a letter dated Monday, Sen. Bill Cassidy (R-La.) accused the FDA of failing to take responsibility for an issue that has long vexed a growing number of people over the implications for the availability of lower-cost gen
Drug Topics
OCTOBER 1, 2024
Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.
Outsourcing Pharma
OCTOBER 1, 2024
The Barcelona-based startup Sequentia Biotech has raised â10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.
STAT
OCTOBER 1, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Not so Midwest nice Vice presidential debates don’t usually matter much, but this one might. It’s probably the last chance for a one-on-one matchup between the two parties’ tickets in a very close race.
Outsourcing Pharma
OCTOBER 1, 2024
Artificial intelligence has emerged as a potential solution to inconsistent reporting of adverse events, which to this day remains one of the main challenges in the field of pharmacovigilance.
STAT
OCTOBER 1, 2024
As a public health professional, I want people to have access to the health care they need to improve their quality of life. For years I researched available treatments for specific illnesses to determine their safety and efficacy, growing to become an advocate for the development of new treatments for those living with rare diseases. Yet, for too long, I had no idea the Food and Drug Administration convenes groups of experts, known as advisory committees or ad comms, to review trial data for tr
Fierce Pharma
OCTOBER 1, 2024
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million shares in Haleon for 380 pence (roughly $5.09) apiece. The sale amounts to a total value of 2.43 billion pounds sterling (about $3.26 billion) and follows a similar move in March.
STAT
OCTOBER 1, 2024
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.
Fierce Pharma
OCTOBER 1, 2024
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the effects.
STAT
OCTOBER 1, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Abridge unveils new research collaborative with Epic, Stanford In an announcement shared exclusively with STAT, ambient documentation darling Abridge says it’s launching a new research effort to examine the technology’s impact on five dimensions: “ clinic
Fierce Pharma
OCTOBER 1, 2024
For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow-walked its request for FDA approval of blood cancer drug Breyanzi to av | For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow-walked its request for FDA approval of blood cancer drug Breyanzi to avoid paying $6.4 billion to Celgene shareholders in contingent value rights.
STAT
OCTOBER 1, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! We’ve got a vice presidential debate tonight. What do you think of the decision by CBS not to have moderators fact-check the candidates like ABC did for the presidential debate? (Watch this space tomorrow for a recap of health and medicine topics that come up.
Expert insights. Personalized for you.
200 
Let's personalize your content